Work

Poster: MPN-127: Add-On Parsaclisib (a PI3Kδ Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study

Year: 2021

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)01457-9

Authors: Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice Wang, Aaron Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O’Connell, Swati Goel, Stephen Oh, Gary Schiller, Albert Assad, Sue Erickson-Viitanen, Xuejun Chen, Feng Zhou, Naval Daver

Institutions: The University of Kansas Cancer Center, Oregon Health & Science University, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Roswell Park Comprehensive Cancer Center, Cleveland Clinic, Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai, Emory University, University of Southern California, Montefiore Medical Center, Washington University in St. Louis, University of California, Los Angeles, Incyte (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200299712

FWCI:

Cites:

Cited by:

Related to: 10